Rheumatic disease and COVID-19: epidemiology and outcomes.
Where this comes from
- Record sourced from PubMed, PMID 33339986.
- Also identified by DOI 10.1038/s41584-020-00562-2 and PMC identifier 7747184.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Since the outset of the COVID-19 pandemic, numerous risk factors for severe disease have been identified. Whether patients with rheumatic diseases, especially those receiving DMARDs, are at an increased risk of SARS-CoV-2 infection or severe COVID-19 disease remains unclear, although epidemiological studies are providing some insight.
Medical subject headings
- Antirheumatic Agents
- COVID-19
- Rheumatic Diseases